PUBLIC COMPANY
save$SLNOSOLENO THERAPEUTICS INC
$SLNORedwood City, CA, USupdated 21d ago
community read0 votes
pipeline
1
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Insider activity
source: SEC Form 4open-market buys + sells
- Mar 27, 26SELLManning Meredith· Chief Commercial Officer−$146K↗
- Mar 27, 26SELLHuang Michael F.· Sr. VP of Clinical Development−$128K↗
- Mar 27, 26SELLManning Meredith· Chief Commercial Officer−$65K↗
- Mar 27, 26SELLHuang Michael F.· Sr. VP of Clinical Development−$57K↗
- Mar 27, 26SELLManning Meredith· Chief Commercial Officer−$18K↗
- Mar 27, 26SELLHuang Michael F.· Sr. VP of Clinical Development−$15K↗
routine RSU / option mechanics (2)
- Mar 2, 26grantFulk Jennifer · CHIEF FINANCIAL OFFICER39,200 sh
- Mar 2, 26option exerciseFulk Jennifer · CHIEF FINANCIAL OFFICER67,660 sh
🐶 Hiring Signal
News
- Deaths reported after treatment with Neurocrine’s approved Prader-Willi drugReports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day f…biospace · 8d ago
- FDA hold puts Aardvark Prader-Willi drug in limboThe company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.biopharma_dive · 3mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that